- Home
- Research
- Research Centres and Centres of Excellence
- ProsTIC
- ProsTIC key research
Our key publications
Latest Published Research
- The ENZA-p Phase 2 Trial: Lu-PSMA with Enzalutemide in patients with metastatic castration-resistant prostate cancer.
- The Lancet Comission On Prostate Cancer: Planning for the surge in cases.
- The LuTectomy Trial: Lu-PSMA prior to radical prostatectomy.
- The TheraP Phase 2 Trial: Lu-PSMA vs Cabazitaxel in metastatic castration-resistant prostate cancer.
- [68Ga]Ga-DPI-4452: First-in-human safety, imaging, and dosimetry of the peptide in patients with clear cell renal cell carcinoma.
Selected Top 10 Research papers with Impact
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 February 11.
Practice changing first RCT of 177Lu-PSMA-617, a novel treatment for men with metastatic prostate cancer. First author and study chair. Oral presentations at ASCO Annual and ASCO GU: 2020, 2021, 2022 - Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet Oncol. 2020
Landmark 10-site RCT establishing PSMA PET/CT as a new standard-of-care in comparison to CT/bone scanning. Presented as EAU20 plenary. FDA approval of 68Ga-PSMA-11 2020. Cited in 2021 NCCN guidelines - 18F-fluciclovine PET-CT vs 68Ga-PSMA-11 PET-CT: a prospective, single-centre, single-arm, comparative imaging trial. Lancet oncol. 2019
Practice changing study, contributed to FDA approval 2020 - Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022
- [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet oncol. 2018 June 1.
First-in-field publication. Led to Endocyte/AAA / Novartis $2b acquisition, multiple ph2/3 studies. - Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiograph. 2018
Highly cited Radiographics manuscript based on award winning RSNA presentation - Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urol. 2016
Widely cited meta-analysis. 2020 update also published with >350 citations - The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med. 2022
- The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021
Awarded EAU Scientific Manuscript of the Year 2021 - PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022
Other Original Research
- Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. 2023
- TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023
- Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2023
- Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis, 2023
- Dose-Response Relationship Between Radiation Therapy and Loss of Lung Perfusion Comparing Positron Emission Tomography and Dual-Energy Computed Tomography in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023
- Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nat Commun. 2023
- A VISION Substudy of Reader Agreement on 68GaPSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. BJU Int. 2023
- Novel radionuclide therapy combinations in prostate cancer. Therapeutic Advances in Medical Oncology, 2023
- Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023
- PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023
- A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. Eur Urol Open Sci. 2023
- A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology. 2023
- Treatment de- intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU Int. 2023
- Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. BJU Int. 2023
- Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy. EJNMMI Res. 2023
- Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer. Front Oncol. 2023
- Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2023
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023
- Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023
- Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study. PLoS One. 2022
- A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med. 2023
- Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging. 2022
- PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. Cancers (Basel). 2022
- Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. Front Oncol. 2022.
- Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2022
- 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. J Nucl Med. 2022
- High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int. 2022
- Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med. 2022
- The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021
- Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: patient experiences. BMJ Support Palliat Care. 2021
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021
- ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021
- Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2021
- UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer. BJU Int. 2021
- Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. Front Med 2021
- Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. EJNMMI Phys. 2021
- The role of 18F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study. J Surg Oncol. 2021
- Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging. 2021
- Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. Eur Urol. 2021
- Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Intern Med J. 2021
- Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2020
- Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020
- Efficacy and Safety of 177Lu-labeled Prostate- specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020
- Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer. BJU Int. 2020
- Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer. Eur Urol 2020
- 68Ga-PSMA PET in advanced prostate cancer - updated diagnostic utility, sensitivity and specificity and distribution of PSMA-avid lesions: A systematic review and meta-analysis. Eur Urol 2020
- Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial. Eur Urol (in press).
- Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2021
- UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021
- Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int. 2020
Review Articles and Clinical Guidelines
- Role of FDG PET/CT in Management of Patients with Prostate Cancer. Semin Nucl Med. 2023.
- Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023
- Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023
- Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2023
- The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. J Nucl Med. 2022
- Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023
- Next Generation Radiotheranostics Promoting Precision Medicine. Ann Oncol. 2023
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023
- Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023.
- [68 Ga]Ga-PSMA Versus [18 F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol. 2022
Winner European Urology Oncology #SoMe award (most influential article according to PlumX Metrics) - 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. Radiology. 2023
- Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022
ASCO 2022 Educational Feature Presentation - Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022
- Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021
- Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021
- Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021
- Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021
- The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA- PET. Eur J Nucl Med Mol Imaging. 2021
- Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021
- Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021
- Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 .
- Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer. Curr Opin Urol. 2020
- PSMA Theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020
- Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat Rev Urol. 2020 .
- Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2019
- The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Curr Opin Urol. 2019
- Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019
Editorials and Commentaries
- The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics. J Nucl Med. 2023
- FAPI PET/CT: a new kid on the block for RCC. Eur J Nucl Med Mol Imaging. 2023
- Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation. J Nucl Med. 2023
- Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging? J Nucl Med. 2023
- Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU Int. 2023
- Editorial Comment on Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023
- More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. Eur Urol. 2023
- Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers. J Nucl Med. 2022
- Leading in Urology and Pioneering in Social Media Outreach: A Conversation J Nuc Med, 2022
- EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022
- Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU Int. 2022
- Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. J Nucl Med. 2021
- Targeted radioactive therapy for prostate cancer - Authors' reply. Lancet. 2021
- Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais. J Nucl Med. 2021
- PSMA PET/CT for staging and treatment of prostate cancer. Clin Adv Hematol Oncol. 2019
- Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength? Eur Urol. 2019
- Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. 2019
- A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naïve vs Post-Taxane metastasized Prostate Cancer Patients? J Nucl Med. 2019
- Where to Next for Theranostics in Prostate Cancer? Eur Urol Oncol. 2019
- Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019
- Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. Eur Urol. 2019